Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

被引：15
作者：
Dejager, Sylvie [1 ]
Schweizer, Anja [2 ]
Foley, James E. [3 ]
机构：
[1] Novartis Pharma SAS, 2 & 4 Rue Lionel Terray, F-92506 Rueil Malmaison, France
[2] Novartis Pharma AG, Basel, Switzerland
[3] Nova Pharmaceut Corp, E Hanover, NJ USA
来源：
VASCULAR HEALTH AND RISK MANAGEMENT | 2012年 / 8卷
关键词：
vildagliptin; type; 2; diabetes; dipeptidyl peptidase-4 inhibitors; monotherapy; elderly;
D O I：
10.2147/VHRM.S31758
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, as monotherapy have been widely confirmed in a large body of clinical studies of up to 2 years' duration in various populations with type 2 diabetes mellitus. This paper reviews the data supporting the use of vildagliptin in monotherapy. Consideration based on baseline glycated hemoglobin levels and age is given to patient segments where metformin is not appropriate. In addition, although prediabetes is not an indication, this manuscript briefly reviews some of the existing data showing that the mechanisms at work in diabetic populations are active in patients currently classified as prediabetic, with impaired glucose tolerance or impaired fasting glucose. Finally, the rationale for vildagliptin dosing frequency in monotherapy is discussed. In summary, this review aims to define where in community practice the use of vildagliptin as monotherapy is most desirable, focusing on segments of the population with type 2 diabetes mellitus that might receive the greatest benefit from vildagliptin in the management of their disease.
引用
收藏
页码：339 / 348
页数：10
相关论文
共 54 条
[1]   The islet enhancer vildagliptin:: mechanisms of improved glucose metabolism [J].
Ahren, B. ;
Foley, J. E. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 :8-14
[2]   Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes [J].
Ahrén, B ;
Landin-Olsson, M ;
Jansson, PA ;
Svensson, M ;
Holmes, D ;
Schweizer, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2078-2084
[3]   Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans [J].
Ahren, B. ;
Schweizer, A. ;
Dejager, S. ;
Villhauer, E. B. ;
Dunning, B. E. ;
Foley, J. E. .
DIABETES OBESITY & METABOLISM, 2011, 13 (09) :775-783
[4]   Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin [J].
Ahren, B. ;
Foley, J. E. ;
Bosi, E. .
DIABETES OBESITY & METABOLISM, 2011, 13 (03) :193-203
[5]   Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes [J].
Ahren, Bo ;
Schweizer, Anja ;
Dejager, Sylvie ;
Dunning, Beth E. ;
Nilsson, Peter M. ;
Persson, Margaretha ;
Foley, James E. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (04) :1236-1243
[6]   Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes [J].
Aubert, R. E. ;
Herrera, V. ;
Chen, W. ;
Haffner, S. M. ;
Pendergrass, M. .
DIABETES OBESITY & METABOLISM, 2010, 12 (08) :716-721
[7]   Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes [J].
Azuma, Koichiro ;
Radikova, Zofia ;
Mancino, Juliet ;
Toledo, Frederico G. S. ;
Thomas, Ernestine ;
Kangani, Cyrous ;
Man, Chiara Dalla ;
Cobelli, Claudio ;
Holst, Jens J. ;
Deacon, Carolyn F. ;
He, YanLing ;
Ligueros-Saylan, Monica ;
Serra, Denise ;
Foley, James E. ;
Kelley, David E. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (02) :459-464
[8]   Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes [J].
Barnett, A. H. ;
Cradock, S. ;
Fisher, M. ;
Hall, G. ;
Hughes, E. ;
Middleton, A. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (08) :1121-1129
[9]   Metformin and digestive disorders [J].
Bouchoucha, M. ;
Uzzan, B. ;
Cohen, R. .
DIABETES & METABOLISM, 2011, 37 (02) :90-96
[10]  
Bourdel-Marchasson Isabelle, 2011, Hosp Pract (1995), V39, P7, DOI 10.3810/hp.2011.02.369
123456